We examined the effects of arachidonic acid metabolites on the simultaneous expression of procoagulant (PC) and plasminogen activator (PA) activities by rabbit alveolar macrophages. Incubation with lymphocyte-conditioned medium (LCM) caused a significant increase in cell-associated PC activity. Co-treatment with indomethacin (1 @I) reduced this augmentation in PC activity by 33% (p < 0.05). In contrast, indomethacin caused a 42% increase in PA activity released into incubation medium (p < .OS). Both effects of indomethacin were reversed by the addition of PGE2 in concentrations as low as 1 nM. Addition of 100 nM PGE2 to these cells caused an increase in PC activity 2.7-fold greater than that achieved by LCM alone, while PGE2 suppressed released PA activity by 62%. PGE2 and indomethacin had similar but less pronounced effects on phorbol myristate acetate-treated cells. These effects of PGE2 could be duplicated by PGEr, but not by any other arachidonic acid metabolite (PGFza, PGI2, PGD2, ddPGFzcc, LTB4, or LTC4). While PGE2 increases intracellular levels of CAMP, the observed effects on PC and PA activities could not be reproduced fully by treatment with dibutyryl CAMP. We conclude that PGE2 amplifies the augmentation of PC activity by stimulated alveolar macrophages while concurrently inhibiting expression of plasminogen activator. This suggests that PGE2 may be a significant mediator in regulating the highly interactive processes of inflammation and coagulation/fibrinolysis.
INTRODUCTION
Arachidonic acid metabolites are increasingly recognized as important in regulating expression of inflammatory responses (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . We previously demonstrated that prostaglandin (PG)E;! is necessary for the augmented expression of procoagulant (PC) activity by rabbit alveolar macrophages stimulated by bacterial lipopolysaccharide. This observation led us to hypothesize that PGE;! may represent an important regulatory link between inflammatory and coagulation pathways (17). However, macrophages also promote fibrinolysis, chiefly by elaborating a plasminogen activator (PA) (l&19). Thus, the net effect of macrophages on fibrin turnover during inflammation must be viewed in the context of the simultaneous expression of competing procoagulant and fibrinolytic activities. Because there is limited evidence that PGE2 suppresses plasminogen activator activity of elicited macrophages (20,21), we undertook to expand our earlier study by examining the role of cyclooxygenase and lipoxygenase metabolites on the concomitant expression by macrophages of both procoagulant and plasminogen activator activities.
METHODS
Animals -Male New Zealand white rabbits (1.5 to 2 kg) were given routine care in the Unit for Laboratory Animal Medicine, University of Michigan Medical Center.
Bm
-Rabbits were sacrificed by intravenous injection of sodium pentobarbital and exsanguinated prior to lavage. The trachea was cannulated and the lungs lavaged with 35 ml aliquots of Dulbecco's talcum-magnesium-free phosphate buffered saline (PBS; Gibco, Grand Island, NY) at 37'C until 300 ml of lavage fluid was returned. Cell pellets were treated with 110 mM ammonium chloride in 100 r&i Tris buffer (pH 7.0) to lyse contaminating erythrocytes. The cells were then washed three times in serum-free culture medium consisting of RPMl-1640 (Gibco) containing penicillin (100 U/ml), streptomycin (100 pg/ml), gentamicin (100 pg/ml), polymixin B (100 U/ml), and lactalbumin hydrolysate (0.2%, Gibco). In all cases, cell viability was greater than 95% by trypan blue exclusion. Cell preparations were consistently more than 95% alveolar macrophages (22).
Prenaration of Additives. Lymphocyte-conditioned medium (LCM) was used as a crude source of lymphokines.
Lymphocyte suspensions were prepared from normal rabbits as described previously (19) . Cell suspensions were prepared in standard culture medium from the nonadherent cells of minced paraortic lymph nodes (> 95% lymphocytes) and incubated in 75 ml culture flasks (Falcon Labware, Oxnard, CA) for 48 hours at 5 x lo6 cells/ml in medium containing Concanavalin A bound to Sepharose 4B beads (5 pg/ml Con A; Pharmacia Chemicals, Piscataway, NJ). After incubation, the LCM was freed of cells and Con A-Sepharose by cenhifugation, sterilized by filtration, and stored at -7O'C. Preliminary experiments indicated that a 1:8 dilution of LCM was optimal, and one such preparation was used in all subsequent experiments. Prostaglandins (PG) and leukotrienes (LT) were generous gifts of the Upjohn Corporation, Kalamazoo, MI. All were stored at -20°C in ethyl alcohol. Indomethacin (Sigma) was freshly dissolved in ethyl alcohol (10 mg/ml). All additives were further diluted in culture medium such that the final concentration of ethyl alcohol in cell cultures did not exceed 0.01%. The semiselective lipoxygenase inhibitors nordihydroguiaretic acid (NDGA; Aldrich Chemicals, Milwaukee, WI) and nafazatrom (Burroughs Wellcome, Research Triangle, NC) were dissolved directly in culture medium. Phorbol myristate acetate (PMA; Consolidated Midland, Brewster, NY) was stored at -20°C dissolved (1 mg/ml) in dimethylsulfoxide (DMSO) and freshly diluted in culture medium for each experiment so that the final DMSO concentration did not exceed 10 parts per million.
Cell Culture. One million cells were dispensed in 1 ml of the serum-free culture medium and incubated in duplicate in sterile 12 x 75 mm polypropylene tubes for 24 hours at 37'C in 5% CO2-enriched air. Cells were exposed to the various additives for the entire incubation period, as indicated. Following incubation, the cells were collected by centrifugation and resuspended in 1 ml of fresh medium. Both cell suspensions and conditioned incubation media were stored at -20°C prior to assay. sonication.
Cell lysates were prepared for assay by two cycles of freeze-thawing followed by . .
Procoagulant Acav ltv Assay. Procoagulant activity was measured using a one-stage coagulation assay (22). Briefly, 100 ~1 volumes of test material, 25 mM CaC12, and titrated normal rabbit plasma were mixed sequentially at 37'C and the time required for fibrin formation was measured with a coagulation timer (BBL Fibrosystem, Cockeysville, MD). Coagulation times of each sample were measured twice and averaged (measurements consistently agreed within lo-15%). The means of the duplicate samples were then translated into arbitrary units of PC activity using a standard curve based on the linear relationship between the log concentration of procoagulant material and the log of the msultant coagulation time (22) . Preliminary experiments confirmed our prior observations that only a smal1 fraction of the PC activity generated by these cells was released into the culture medium, and that the released activity varied in parallel with cell-associated activity (22). Accordingly, we routinely assayed PC activity only in cel1 lysates. None of the pharmacologic agents used in the study affected the assay for PC activity.
Plasminouen Activator Assav, PA activities of incubation media and cel1 lysates were measured with a modified 1~1~fibrin plate assay, as described previously in detail (18, 19) . In brief, 60 pg of human fibrinogen (Kabi, Stockholm, Sweden) containing 2 x 105 cpm of 1251-labeled fibrinogen (Amersham, Arlington Hts, IL) was dried onto 16 mm plastic culture wells and converted to fibrin with 5% fetal bovine serum (Gibco). Human plasminogen was purified by lysine-Sepharose affmity chromatography (23) and added in an optimal concentration (2 to 6 pg protein/ml) along with test samples to the fibrin wells. lzI activity released into the incubation medium was measured after 4 hours at 37OC. The cpm xeleased only in the presence of test sample and plasminogen was taken to represent PA activity. Net lui release was calculated as the percent of maximal release achieved by trypsinizing the wells; percent lysis was then translated into milliPlough units @PU) using a standard curve generated with human urokinase (Sigma Chemicals, St. Louis, MO). 1251 release was negligible in the absente of added plasminogen; therefore, plasminogen-independent fibrinolysis was not examined further. None of the pharmacologic interventions affected the t*sI-fibrin assay. It is important to emphasize that this assay only measures plasminogen-dependent fibrinolysis, and the results may reflect changes in either plasminogen activator proteins or plasminogen activator inhibitors. Therefore, PA is only discussed in terms of activity, and not concentrations of specific proteins.
Cvclic Adenosine Mononhosnhate (cAM.P) Assav, Intracellular cAMP levels were measured with a double antibody radioimmunoassay (24). The limit of sensitivity was 10 fmole/ml, and interand intra-assay variabilities were 2.7% and 2.9%, respectively. This assay only cross-reacted with ó-fold greater concentrations of adenosine monophosphate and at least 400-fold greater concentrations of other purine nucleosides and nucleotides. Assays were performed by the laboratories of the Diabetes Training and Research Center, University of Michigan Medical Center.
Multiple comparisons to control groups were perfomud using Dunnett's test applied to Statistics. a one-way analysis of variante. Single comparisons were tested with the unpaired Student's t test (25).
RESULTS
Pr acron ocoauu an and nlasminouen activator activities of normal a d st 1 t imul ated h=In keeping with our previous studies (19, 22) , fìeshly isolated alveoyar macrophagi expressed both procoagulant and plasminogen activator activities (Table 1) . Cell lysates accelerated coagulation of normal plasma to 197 f 3 1.6 s, compared to spontaneous coagulation times of recalcified plasma consistently greater than 500 sec. When cells were incubated for 24 hours in standard culture medium, there was a modest but significant increase in PC activity (105 f 7.7 sec; p c 0.001). The addition of LCM to the culture medium caused a further increase in PC activity (88.5 t 6.7 sec; p < 0.05). Maximal stimulation with PMA (10 nM) caused a marked incmase in procoagulant activity (47.1 f 3.6 sec; p < 0.001). Prior studies have shown that this procoagulant activity functions as a tissue thromboplastin, activating the extrinsic coagulation pathway (22).
Lysates of freshly isolated macrophages expres& low levels of plasminogen activator activity (93.8 f 25 mPU/106 cells). When cells were cultured for 24 hours, the lysate activity increased to 358 i: 84 mPU/106 cells (p < 0.001). In addition, 642 f 155 mPU/ml was present in the culture medium. LCM did not affect expression of PA in either lysates or incubation media (p > 0.5), but PMA caused marked incteases in both activities (Table 1) . We have shown that this plasminogen activator has immunologie and molecular weight characteristics of a urokinase rather than a tissue plasminogen activator (26). Preliminary experiments (not shown) verified that the effects of LCM and PMA on PC and PA activities were not affected by the presence or absente of polymyxin B, indicating that the effects were not due to contaminating endotoxin (17). C mvmes of LCM-tr& cells, Co-treatment with indofmetl!acin (1l.M) blunted the I!CM-stimulated increase in PC activity by 33% (pcO.O5* Figure 1A ) This cotresponded to prolongation in coagulation times to 100.1 f 6.1 seconds (p ; 0.1). The inhibitory effects of indomethacin were completely reversed by the addition of PGE2 in concenuations as low as 1 nM. Higher concentrations of PGE2 further augmented the resultant PC activity, with 100 nM concentrations stimulating almost 3-fold greater PC activity compared to cells treated with LCM alone ( Figure 1A ). This represented a decrease in coagulation times to 72.6 f 3.6 seconds (pcO.001). Neither indomethacin nor PGE2 alone altered PC activity unless a conditioning stimulus such as LCM was present, confirming our prior observations (17).
The PA activities in lysates and incubation media from control cells were variable, but indomethacin caused consistent and significant increases in PA activity released into incubation media, reaching 142% of control vahres (pc 0.05; Figure 1B) . Addition of PGE2 in doses as low as 1 nM reversed the effect of indomethacin, while higher concentrations caused further suppression of PA activity. The effect was dose-related, with 100 nM PGE2 maximally suppressing both cell-associated and released PA activities to 33% and 38% of controls, respectively (p< 0.01). In time course studies, the effects of PGE2 on PC and PA activities both appeamd after incubation for 8 hours. Unlike the augmentation of PC activity, the suppression of PA activity by PGE2 did not require co-treatment with a conditioning stimulus such as LCM, as identical suppressive effects were seen when PGE2 was added alone to normal rabbit alveolar macrophages (not shown).
To determine if augmentation of PC and suppression of PA activities were specific to PGE2, macrophages were incubated with LCM, indomethacin (1 PM), and PGE2, PGEl, PGF2a, PGI2, Of the 5 prostaglandins examined, only PGEp stimulated an increase in PC activity, reversing the effects of indomethacin. BOTTOM: Both PG& and PGEt markedly suppmssed PA activities of cell lysates and incubation media, but the other prostaglandins had no effect. PGD2, and the synthetic thromboxane mimic ddPGF2a. In al1 cases, concenuations ranging from 1 to 10,000 nM were evaluated, and representative results (100 nM) are shown in Figure 2 . Gnly PGE2 could reverse the effect of indomethacin on PC activity (Figure 2A ), while both PGE2 and PGEr suppressed expression of PA activity ( Figure 2B ), indicating these effects are specific to prostaglandins of the E series. During these studies, we noted that LCM caused a slight but relatively consistent decrease in PA activity. In a prior study, another lot of LCM prepared in identical fashion caused modest increases in PA activity (19) . In light of the potent suppressive effects of even 1nM PGE2, we sought to determine if the variability between lots of LCM could be explained by presence of trace amounts of PGE2. Indeed, the LCM preparation used in this study contained 0.1 nM immunoreactive PGE2 by radioimmunoassay, raising the possibility that trace contamination with PG& could have intluenced the effect of LCM on macrophage PA activity.
Effects of PGE, on PMA-stimulated macroDhag!$& We sought to determine if PGE2 had similar modulating effects on macrophages maximally stimulated by PMA, which unlike LCM stimulates marked increases in both PC and PA activities. The addition of indomethacin (1 p.M) consistently and significantly (p < 0.05) reduced the PC activity of PMA-stimulated macrophages, although the remaining activity was stil1 much higher than unstimulated cells @gure 3A). PGE2 and PGEr completely reversed the suppressive effects of indomethacin, while PGF@ had no effect. Indmthacin caused a 38% increase in PA activity mleased by PMA-stimulated cells (p < 0.05)
The effects of indomethacin and PG's (100 nM) on PC and PA activities of rabbit alveolar macrophages maximally stimulated with PMA (10 nM). Data are expressed as % of control values from cells incubated with PMA alone. Mean f SEM, N=4. Differences between bracketed groups for which p c .05 are denoted by an asterisk. Tpp: PC activity. The increase in PC activity above that of freshly harvested cells is displayed on the ordinate at the left. Corresponding coagulation times are shown on the ordinate at the right (log scale). Indomethacin suppressed the augmentation of PC activity of PMA-treated cells by 20%. Addition of either PGE2 or PGEr completely reversed this effect. In contrast, PGF2a had no effect on PC activity.. BO'ITOM: PA activity. Indomethacin stimulated a 38% increase in PA activity released into incubation media. This effect was also reversed by PGEp and PGEr, but not PGF2cx.
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Again, this effect was reversed by PGE2 and PGEt, but not PGF2a ( Figure 3B ). Although the changes induced by indomethacin and PGE were smaller in pmportion to the high levels of these activities stimulated by PMA, these results are qualitatively similar to those of LCM-treated cells.
To determine if pnxlucts of the lipoxygenase pathway can also alter macrophage PC and PA activities, cells were tmated with the semiselective lipoxygenase inhibitors NDGA (1@4) or nafazatrom (1 @vi). When used in doses that should not signitkantly inhibit cyclooxygenase activity (27), neither agent had any consistent effect on either PC or PA activity of normal or LCMtreated cells (not shown). Further, addition of LTB4 and LTC4 (0. l-10 nM) had no significant effect on either activity in normal macrophages or in cells submaximally stimulated witb PMA (2 nM) (not shown). Taken together, these results suggest that leukotrienes have considerably less effects, if any, on these macrophage functions compared to prostaglandin E2.
Role of cAMP in PGET-Mediated Effects on PC and PA Activities, To determine if PGE modulates macrophage PC and PA activities by altering adenylate cyclase activity (28,29), we fust examined the effect of PGE2 on intracellular levels of cAMP. The addition of PGE2 (100 pM) to normal macrophages cultured for 60 minutes increased intracellular levels of cAMP by 77 zk 30%, compared to control values (p < 0.05). Experiments were then performed to determine if exogenous cAMP could mimic the effects of PGE2 on PC and PA activities. Dibutyryl cAMP (dbcAMP;lpM to 1mM) was added to standard macrophage cultures for 24 hours. As shown in Figure 4 , an optimal concentration of db-cAMP (1mM) acted like PGE2 in decreasing release of PA activity by both normal macrophages (42% control; p < 0.05) and cells submaximally stimulated by 2 nM PMA (57% control; p < 0.01). Lysate PA activities were similarly decreased by 57% and 59% (p < O.Ol), respectively (not shown). However, db-cAMP had no consistent effect on PC expression by normal or PMA-stimulated macrophages. Dibutyryl-cAMP suppressed released PA activities of unstimulated and PMA stimulated macrophages by 48% and 52%, respectively (p < 0.05). db-cAMP had no consistent effect on PC activity in either group.
Interactions between mononuclear phagocytes and the coagulation and fibrinolytic pathways appear to have a role in the pathogenesis of delayed-type hypersensitivity and other inflammatory conditions (30, 31) . Expression by mactophages of both procoagulant and plasminogen activator activities are augmented in vin-0 by activated lymphocytes or their products (32) (33) (34) (35) . Similarly, stimulation of both monocyte plasminogen activator and procoagulant activity has been shown to be in vin0 correlates of cell mediated immunity in vivo (34, 35) . The competing interplay between procoagulant and fibrinolytic activity may regulate local accumulation of fibrin matrix. These íïlnin Vol. 51, No. 5 matrices potentiaIly contribute to many aspects of infhunmatory responses, as fibrinogenderived products are chemotactic for leukocytes, inhibit lymphocyte function, affect macrophage mobility, and provide a favorable substrate for ingrowth of fibroblasts (35-39). We therefore sought to expand on earlier observations (17, 20, 21) by examining the effects of arachidonic acid metabolites on concurrent expression of tissue thromboplastin and plasminogen activator activities by rabbit alveolar macrophages.
We found that indomethacin suppressed augmentation of PC activity of LCM and PMA-treated macrophages, while stimulating both released and cell-associated plasminogen activator activity (Figures 1 and 3) . These effects of indomethacin could only be reversed by addition of exogenous PGE and not by any other cyclooxygenase metabolite tested @gure 2). This indicates that indomethacin affects macrophage PC and PA activities by blocking endogenous production of PGE2. Exogenous PGE2 enhanced PC suppression beyond the leve1 of maximal stimulation by LCM alone, while the same concentrations markedly suppressed PA activity. PGE2 had a qualitatively similar but smaller effect on the markedly elevated PC and PA activities of PMAstimulated macrophages. It is notable that PGE2 only augmented PC activity of cells that were conditioned by a second stimulus, but suppressed PA production by both normal and conditioned macrophages. Thus, PG& may have differential effects on these two activities depending on the degree to which macrophages are co-stimulated with inflammatory mediators.
Most of the effects of PGE2 on leukocyte functions are presently believed to occur by stimulating adenylate cyclase activity (28, 29) . This prompted US to consider whether intracellular cAMP levels ultimately regulate expression of PC and PA activities. Treating normal or PMAconditioned macrophages with dibutyryl cAMP caused only a variable and statistically insignificant increase in PC activity, but suppression of PA was comparable to the maximal effect of PGEp @gure 4). However, it is clear that augmentation of intracellular cyclic AMP is not a sufficient explanation for the effects of PGE2, as we have found that stimulating these cells with adenosine analogues under identical culture conditions causes a similar increase in inuacellular cyclic AMP, but opposite directional changes in both PC and PA activites (40). Thus, it appears that modulation of adenylate cyclase activity is either compartmentalized to agonist-specific sites, or altematively, PGEp may affect cellular functions by mechanisms unrelated to cyclic AMP.
The modulation by PGE2 of both tissue thromboplastin and plasminogen activator activities is certainly consistent with a growing body of evidente that mononuclear phagocytes exert feedback inhibition on many effector functions through endogenous secretion of PGE2. This arachidonic acid metabolite is known to have suppressive effects in vitro on macrophage proliferation, production of complement proteins and oxygen metabolites (l-6), and more recently, expression of histocompatibility antigens, and release of interleukin-1 and tumor necrosis factor (7-9). In contrast, PGE2 enhances expression of FC receptors and collagenase production while phagocytosis and tumor killing are variably affected (10-15). Some of these effects may be responsible for the modulation of cell mediated immune reactions by arachidonic acid metabolites in vivo (16).
To summarize, we have shown that PGE2 has opposite modulating effects in vitro on expression by rabbit alveolar macrophages of tissue thromboplastin and plasminogen activator activities. These combined effects may interact to promote fibrin accumulation at inflammatory foei. If this is so, this would establish PGE2 as an important mediator interrelating the processes of inflammation and coagulation/fibrinolysis. These results further suggest that cyclooxygenase inhibitors and exogenous PGE2 may be useful in future studies to investigate the role of tïbrin matrix deposition in the pathogenesis of inflammation and tissue repair. Finally, it is clear that the potential influences of contaminating or endogenously produced PGE2 must be considered in future studies of macrophage procoagulant and plasminogen activator activities.
